(no title)
jorlow
|
2 years ago
The article says "patients must undergo a preparatory treatment with a chemotherapy drug to remove any native stem cells that might remain in their bone marrow." It doesn't make much difference to the patient if it's the Lyfgenia itself or the chemo drug, if the chemo drug is a requirement. Right?
skissane|2 years ago
https://med.stanford.edu/news/all-news/2019/05/radiation-fre...
There is also ongoing research into immunotherapy for killing stem cells, as an alternative to the existing methods of chemotherapy and radiation. Potentially, immunotherapy could have significantly reduced secondary cancer risk.
https://jhoonline.biomedcentral.com/articles/10.1186/s13045-...
confused_boner|2 years ago
unknown|2 years ago
[deleted]
eszed|2 years ago
Does anyone know if changing the drug would require a new FDA approval for the entire regimen, or could the protocol be easily changed?
firejake308|2 years ago
skissane|2 years ago
The FDA-approved prescribing information will recommend a particular chemotherapy regimen, but clinicians will be free to substitute alternatives if they believe those are clinically superior. They won't need permission from the FDA or the manufacturer to do that; clinicians deviate from the FDA-approved manufacturer recommendations all the time ("off-label prescribing").
If the manufacturer wants to update the official recommendations in the prescribing information, then they'll need FDA approval for that. But it is possible for clinicians to publish their own treatment guidelines (e.g. in medical journal articles), independent of the manufacturer, and the FDA has no control over those.
unknown|2 years ago
[deleted]